O przewadze leczenia indukcyjnego nad leczeniem eskalacyjnym stwardnienia rozsianego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2020
Słowa kluczowe:
stwardnienie rozsiane, leczenie indukcyjne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Perspektywy leczenia stwardnienia rozsianego znacznie się zmieniły wraz z zatwierdzeniem ponad 10 nowych leków tylko w ciągu ostatniej dekady. Ale do dziś nie osiągnięto konsensusu co do tego, które terapie powinny być stosowane jako pierwszy wybór, a ostatnio opublikowane międzynarodowe wytyczne różnią się między sobą. Podczas leczenia pacjenta na wczesnym etapie choroby rozważa się podejście eskalacyjne lub indukcyjne. W terapii eskalacyjnej kładzie się nacisk na bezpieczeństwo, podczas gdy w terapii indukcyjnej na skuteczność. Opublikowano wiele rzeczowych artykułów, w których rozważano, czy środki o większej skuteczności powinny być stosowane wcześniej. W pracy przedstawiono argumenty przemawiające za wyższością terapii indukcyjnej nad eskalacyjną.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Tremlett H, Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome? Neurology. 2006; 67: 954-9.
2. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007; 20: 269-74.
3. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic proces. Brain. 2003; 126: 770-82.
4. Langer-Gould A, Popat RA, Huang SM et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006; 63: 1686-91.
5. Giovannoni G, Bermel R, Phillips T et al. Mult Scler Relat Disord. A brief history of NEDA. 2018; 20: 228-30.
6. Calabrese M, Romualdi C, Poretto V et al. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann Neurol. 2013; 74: 76-83.
7. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014; 13: 113-26.
8. Håkansson I, Tisell A, Cassel P et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017; 24: 703-12.
9. Fillippi M, Rocca M. Rethinking multiple sclerosis treatment strategies. Lancet Neurol. 2020; 19(4): 281-2. https://doi.org/10.1016/S1474-4422(20)30063-6.
10. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017; 376: 221-34.
11. Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017; 376: 209-20.
12. Hu Y, Turner MJ, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009; 128: 260-70.
13. Gallo P, Centonze D, Marrosu MG. Alemtuzumab for multiple sclerosis: the new concept of immunomodulation. Multiple sclerosis and Demyelinating Disorders. 2017; 2: 7.
14. Coles AJ, Cohen JA, Fox EJ et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017; 89: 1117-26.
15. Havrdova E, Arnold DL, Cohen JA et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology. 2017; 89: 1107-16.
16. Sigal DS, Miller HJ, Schram ED et al. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010; 116: 2884-96.
17. Giovannoni G, Comi G, Cook S et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med. 2010; 362: 416-26.
18. Giovannoni G, Soelberg Sorensen P, Cook S et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018; 24: 1594-604.
19. He A, Merkel B, Brown JWL et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020; 19(4): 307-16. https://doi.org/10.1016/S1474-4422(20)30067-3.
20. Kalincik T, Jokubaitis V, Spelman T et al. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Mult Scler. 2018; 24(12): 1617-26. https://doi.org/10.1177/1352458517728812.
2. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007; 20: 269-74.
3. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic proces. Brain. 2003; 126: 770-82.
4. Langer-Gould A, Popat RA, Huang SM et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006; 63: 1686-91.
5. Giovannoni G, Bermel R, Phillips T et al. Mult Scler Relat Disord. A brief history of NEDA. 2018; 20: 228-30.
6. Calabrese M, Romualdi C, Poretto V et al. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann Neurol. 2013; 74: 76-83.
7. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014; 13: 113-26.
8. Håkansson I, Tisell A, Cassel P et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017; 24: 703-12.
9. Fillippi M, Rocca M. Rethinking multiple sclerosis treatment strategies. Lancet Neurol. 2020; 19(4): 281-2. https://doi.org/10.1016/S1474-4422(20)30063-6.
10. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017; 376: 221-34.
11. Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017; 376: 209-20.
12. Hu Y, Turner MJ, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009; 128: 260-70.
13. Gallo P, Centonze D, Marrosu MG. Alemtuzumab for multiple sclerosis: the new concept of immunomodulation. Multiple sclerosis and Demyelinating Disorders. 2017; 2: 7.
14. Coles AJ, Cohen JA, Fox EJ et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017; 89: 1117-26.
15. Havrdova E, Arnold DL, Cohen JA et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology. 2017; 89: 1107-16.
16. Sigal DS, Miller HJ, Schram ED et al. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010; 116: 2884-96.
17. Giovannoni G, Comi G, Cook S et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med. 2010; 362: 416-26.
18. Giovannoni G, Soelberg Sorensen P, Cook S et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018; 24: 1594-604.
19. He A, Merkel B, Brown JWL et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020; 19(4): 307-16. https://doi.org/10.1016/S1474-4422(20)30067-3.
20. Kalincik T, Jokubaitis V, Spelman T et al. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Mult Scler. 2018; 24(12): 1617-26. https://doi.org/10.1177/1352458517728812.